(CercleFinance.com) – Sensorion announces that it has enrolled the first patient in its proof-of-concept clinical trial of SENS-401 (Arazasetron) in patients to receive a cochlear implant, after preclinical studies in collaboration with Cochlear.
This phase 2a multicenter, randomized, controlled and open-label trial aims to evaluate the presence of SENS-401 in the cochlea (perilymph) after seven days of twice-daily oral administration in adults before cochlear implantation.
“The trial will also evaluate several secondary endpoints, including, in particular, the modification of the hearing threshold on several frequencies between the start and the end of the study in the implanted ear”, adds the biotechnology company.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
